Biomea Fusion (BMEA) to Release Earnings on Monday

Biomea Fusion (NASDAQ:BMEA) is anticipated to release its earnings data before the market opens on Monday, April 7th. Analysts expect Biomea Fusion to post earnings of ($1.00) per share for the quarter.

Biomea Fusion Trading Down 7.6 %

NASDAQ:BMEA opened at $2.30 on Monday. The stock has a 50 day moving average of $3.32 and a two-hundred day moving average of $6.00. The firm has a market cap of $83.35 million, a P/E ratio of -0.57 and a beta of -0.26. Biomea Fusion has a 12 month low of $2.27 and a 12 month high of $16.29.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BMEA. Oppenheimer set a $10.00 target price on shares of Biomea Fusion in a report on Monday, March 24th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Biomea Fusion in a report on Monday, March 24th. Finally, D. Boral Capital restated a “buy” rating and set a $16.00 target price on shares of Biomea Fusion in a report on Wednesday, March 19th. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Biomea Fusion presently has a consensus rating of “Buy” and a consensus target price of $24.64.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.